Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MISSISSAUGA, ON, July 31, 2013 -- /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the second quarter ended June 30, 2013.
Help employers find you! Check out all the jobs and post your resume.
MISSISSAUGA, ON, July 31, 2013 -- /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the second quarter ended June 30, 2013.
Help employers find you! Check out all the jobs and post your resume.
